小猪视频app

听	听	听
听	OMB APPROVAL	听
听	OMB Number:听3235-0058	听
听	Expires:听April听30, 2009	听
听	Estimated average burden hours per response ... 2.50	听
听

听	听	听
听	SEC FILE NUMBER	听
听	听	听
听	听	听
听	CUSIP NUMBER	听
听	听	听
听

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

听	听	听	听	听	听
(Check one):	听	o听 Form听10-K o听 Form听20-F o听 Form听11-K 镁听 Form听10-Q o听 Form听10-D o听 Form听N-SAR o听 Form听N-CSR
听	听	听	听	听	听
听	听	For Period Ended:	听	March 31, 2007
听	听	听	听
听	听	听	听	听	听
听	听	o听听 Transition Report on Form听10-K			听
听	听	听	听	听	听
听	听	o听听 Transition Report on Form听20-F			听
听	听	听	听	听	听
听	听	o听听 Transition Report on Form听11-K			听
听	听	听	听	听	听
听	听	o听听 Transition Report on Form听10-Q			听
听	听	听	听	听	听
听	听	o听听 Transition Report on Form听N-SAR			听
听	听	听	听	听	听
听	听	For the Transition Period Ended:		听		听
听	听	听	听	听

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I 聴 REGISTRANT INFORMATION

EXEGENICS INC.

Full Name of Registrant

CYTOCLONAL PHARMACEUTICALS, INC.

Former Name if Applicable

4400 Biscayne Blvd, Suite 900

Address of Principal Executive Office (Street and Number)

Miami, Florida 33137

City, State and Zip Code

PART II 聴 RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule听12b-25(b), the following should be completed. (Check box if appropriate)

听	听	听	听	听	听
镁
	听	听	(a)	听	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
	听	听	听	听
	听	听	(b)	听	The subject annual report, semi-annual report, transition report on Form听10-K, Form听20-F, Form听11-K, Form听N-SAR or Form听N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form听10-Q or subject distribution report on Form听10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	听	听	听	听
听	听	听	(c)	听	The accountant聮s statement or other exhibit required by Rule听12b-25(c) has been attached if applicable.

PART III 聴 NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

eXegenics Inc., doing business as Opko Health, Inc. (the 聯Company聰), previously announced the entry into and consummation of the acquisition of two development stage companies on March听27, 2007. Prior to the acquisitions, the Company was a shell company with no active operations.

The Company is unable, without unreasonable effort and expense, to file its Quarterly Report on Form 10-Q for the quarter ended March听31, 2007 on a timely basis because additional time is required for the Company to finalize its conclusion on the accounting for various aspects of the acquisitions. The Company anticipates filing the Form 10-Q no later than the expiration of the five-day extension period.

SEC 1344 (03-05)	听	Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(Attach extra Sheets if Needed)
PART IV 聴 OTHER INFORMATION

(1)

听

Name and telephone number of person to contact in regard to this notification

听	听	听	听	听
Adam Logal听	听	305听	听	575-4148听
(Name)	听	(Area Code)	听	(Telephone Number)

(2)	听	Have all other periodic reports required under Section听13 or 15(d) of the Securities Exchange Act of 1934 or Section听30 of the Investment Company Act of 1940 during the preceding 12听months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
听	听	Yes听镁听听听听听No听o
听

(3)	听	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
听	听	Yes听 o听听听听听No听 镁
听

听
听	听	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
听

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

听	听	听	听	听	听	听
Date	听	May 15, 2007	听	By	听	/s/ Adam Logal
听	听	听	听	听	听	听
听	听	听	听	听	听	Adam Logal
听	听	听	听	听	听	Executive Director of Finance, Chief Accounting Officer and Treasurer